208 related articles for article (PubMed ID: 9396433)
1. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
Lablanche JM; McFadden EP; Meneveau N; Lusson JR; Bertrand B; Metzger JP; Legrand V; Grollier G; Macaya C; de Bruyne B; Vahanian A; Grentzinger A; Masquet C; Wolf JE; Tobelem G; Fontecave S; Vacheron A; d'Azemar P; Bertrand ME
Circulation; 1997 Nov; 96(10):3396-402. PubMed ID: 9396433
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
[TBL] [Abstract][Full Text] [Related]
3. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study.
Meneveau N; Schiele F; Grollier G; Farah B; Lablanche JM; Khalifé K; Machecourt J; Danchin N; Wolf JE; Simpson M; Hak JB; Bassand JP
Eur Heart J; 2000 Nov; 21(21):1767-75. PubMed ID: 11052841
[TBL] [Abstract][Full Text] [Related]
5. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem.
Lablanche JM; Grollier G; Lusson JR; Bassand JP; Drobinski G; Bertrand B; Battaglia S; Desveaux B; Juillière Y; Juliard JM; Metzger JP; Coste P; Quiret JC; Dubois-Randé JL; Crochet PD; Letac B; Boschat J; Virot P; Finet G; Le Breton H; Livarek B; Leclercq F; Béard T; Giraud T; Bertrand ME
Circulation; 1997 Jan; 95(1):83-9. PubMed ID: 8994421
[TBL] [Abstract][Full Text] [Related]
6. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.
Brack MJ; Ray S; Chauhan A; Fox J; Hubner PJ; Schofield P; Harley A; Gershlick AH
J Am Coll Cardiol; 1995 Oct; 26(4):947-54. PubMed ID: 7560622
[TBL] [Abstract][Full Text] [Related]
7. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
Faxon DP
J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
[TBL] [Abstract][Full Text] [Related]
8. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
Hermans WR; Foley DP; Rensing BJ; Serruys PW
Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
Faxon DP; Spiro TE; Minor S; Coté G; Douglas J; Gottlieb R; Califf R; Dorosti K; Topol E; Gordon JB
Circulation; 1994 Aug; 90(2):908-14. PubMed ID: 8044962
[TBL] [Abstract][Full Text] [Related]
10. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
Weintraub WS; Boccuzzi SJ; Klein JL; Kosinski AS; King SB; Ivanhoe R; Cedarholm JC; Stillabower ME; Talley JD; DeMaio SJ
N Engl J Med; 1994 Nov; 331(20):1331-7. PubMed ID: 7935702
[TBL] [Abstract][Full Text] [Related]
12. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW
Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty.
Gimple LW; Herrmann HC; Winniford M; Mammen E
Am J Cardiol; 1999 Jun; 83(11):1524-9. PubMed ID: 10363865
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
Hermans WR; Rensing BJ; Foley DP; Deckers JW; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
J Am Coll Cardiol; 1992 Oct; 20(4):767-80. PubMed ID: 1388181
[TBL] [Abstract][Full Text] [Related]
16. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group.
Erbel R; Haude M; Höpp HW; Franzen D; Rupprecht HJ; Heublein B; Fischer K; de Jaegere P; Serruys P; Rutsch W; Probst P
N Engl J Med; 1998 Dec; 339(23):1672-8. PubMed ID: 9834304
[TBL] [Abstract][Full Text] [Related]
17. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES).
Jørgensen B; Simonsen S; Endresen K; Forfang K; Vatne K; Hansen J; Webb J; Buller C; Goulet G; Erikssen J; Thaulow E
J Am Coll Cardiol; 2000 Mar; 35(3):592-9. PubMed ID: 10716459
[TBL] [Abstract][Full Text] [Related]
18. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR).
Berger PB; Holmes DR; Ohman EM; O'Hanesian MA; Murphy JG; Schwartz RS; Serruys PW; Faxon DP
J Am Coll Cardiol; 1996 Jan; 27(1):1-7. PubMed ID: 8522681
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of the effects of gradual prolonged versus standard primary balloon inflation on early and late outcome. Results of a multicenter clinical trial. Perfusion Balloon Catheter Study Group.
Ohman EM; Marquis JF; Ricci DR; Brown RI; Knudtson ML; Kereiakes DJ; Samaha JK; Margolis JR; Niederman AL; Dean LS
Circulation; 1994 Mar; 89(3):1118-25. PubMed ID: 8124798
[TBL] [Abstract][Full Text] [Related]
20. No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial.
Wöhrle J; Höher M; Nusser T; Hombach V; Kochs M
Can J Cardiol; 2003 Apr; 19(5):495-500. PubMed ID: 12717484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
